½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â Abbott Laboratories, Acandis GmbH, AngioDynamics, Inc., Argon Medical Devices, Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation, Johnson & Johnson Services, Inc. (Cerenovus), LeMaitre Vascular, Inc., Medtronic plc, MicroVention, Inc. (a subsidiary of Terumo Corporation), Penumbra, Inc., Phenox GmbH, Stryker Corporation, Terumo Corporation, Vesalio, LLC. µîÀÌ ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼Ò°³
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå ÀλçÀÌÆ®
½ÃÀå ÇöȲ
½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀΰú ±âȸ
ÇãÇ÷¼º ³úÁ¹Áß ¹ß»ý·ü »ó½Â
±â°èÀû Ç÷ÀüÁ¦°Å¼úÀÇ Áøº¸
¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
³ôÀº ½Ã¼ú ºñ¿ë
PESTEL ºÐ¼®
½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå µ¿Çâ
¹ë·ùüÀÎ ºÐ¼®
COVID-19ÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : Á¦Ç°º°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
Ç÷Àü Á¦°Å±â
ÈíÀÎ ±â±â
Ç÷°ü ½º³×¾î
Á¦6Àå ¼¼°èÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
º´¿ø
±¸±Þ Ŭ¸®´Ð
¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
Á¦7Àå ¼¼°èÀÇ ½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå : Áö¿ªº°
ÁÖ¿ä Á¶»ç °á°ú
¼Ò°³
½Å°æÇ÷ÀüÁ¦°Å ±â±â ½ÃÀå Æò°¡ : Áö¿ªº°, 2020-2034³â
ºÏ¹Ì
ºÏ¹Ì : Á¦Ç°º°, 2020-2034³â
ºÏ¹Ì : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
¹Ì±¹
ij³ª´Ù
À¯·´
À¯·´ : Á¦Ç°º°, 2020-2034³â
À¯·´ : ¿ëµµº°, ÃÖÁ¾ 2020-2034³â
¿µ±¹
ÇÁ¶û½º
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
³×´ú¶õµå
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°º°, 2020-2034³â
¾Æ½Ã¾ÆÅÂÆò¾ç : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
Áß±¹
Àεµ
¸»·¹À̽þÆ
ÀϺ»
Àεµ³×½Ã¾Æ
Çѱ¹
È£ÁÖ
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°º°, 2020-2034³â
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
À̽º¶ó¿¤
³²¾ÆÇÁ¸®Ä«°øÈ±¹
±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°º°, 2020-2034³â
¶óƾ¾Æ¸Þ¸®Ä« : ÃÖÁ¾ ¿ëµµº°, 2020-2034³â
¸ß½ÃÄÚ
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
È®´ë¿Í Àμö ºÐ¼®
È®´ë
Àμö
Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦9Àå ±â¾÷ °³¿ä
Abbott Laboratories
Acandis GmbH
AngioDynamics, Inc.
Argon Medical Devices, Inc.
Boston Scientific Corporation
Edwards Lifesciences Corporation
Johnson & Johnson Services, Inc.(Cerenovus)
LeMaitre Vascular, Inc.
Medtronic plc
MicroVention, Inc.(a subsidiary of Terumo Corporation)
ksm
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
The neurothrombectomy devices market size is expected to reach USD 1,418.33 million by 2034, according to a new study by Polaris Market Research. The report "Neurothrombectomy Devices Market Size, Share, Trends, Industry Analysis Report: By Product (Clot Retrievers, Aspiration/Suction Devices, and Vascular Snares), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The neurothrombectomy devices market focuses on medical instruments designed to remove blood clots from the brain in patients suffering from acute ischemic stroke, helping restore blood flow and prevent neurological complications. The market is experiencing significant growth due to the rising incidence of stroke globally, increasing adoption of minimally invasive procedures, and continuous technological advancements in clot retrieval and aspiration devices. Neurothrombectomy devices market opportunities are emerging in developing regions where improving healthcare infrastructure and awareness are driving demand for advanced stroke treatments. Key trends include the integration of artificial intelligence for stroke diagnosis, expanding clinical research for product innovation, and growing reimbursement support in developed markets. With increasing regulatory approvals and strategic collaborations among market players, the neurothrombectomy devices market is expected to expand further in the coming years.
By product, the clot retrievers segment accounted for the largest share of the neurothrombectomy devices market revenue in 2024 due to their high efficacy in mechanical thrombectomy procedures, while aspiration/suction devices are expected to witness the highest growth due to advancements in vacuum-assisted clot removal technologies.
By end use, the hospitals segment dominated the neurothrombectomy devices market share as they are the primary centers for stroke treatment with well-equipped neurovascular units, while ambulatory surgical centers are experiencing rapid growth due to increasing demand for minimally invasive procedures and faster patient recovery.
North America holds the largest market share due to advanced healthcare infrastructure, high stroke incidence, and strong reimbursement policies, while Asia-Pacific is the fastest-growing region driven by rising healthcare investments, increasing awareness, and improving stroke management facilities.
A few major companies in the market are Abbott Laboratories; Acandis GmbH; AngioDynamics, Inc.; Argon Medical Devices, Inc.; Boston Scientific Corporation; Edwards Lifesciences Corporation; Johnson & Johnson Services, Inc. (Cerenovus); LeMaitre Vascular, Inc.; Medtronic plc; MicroVention, Inc. (a subsidiary of Terumo Corporation); Penumbra, Inc.; Phenox GmbH; Stryker Corporation; Terumo Corporation; and Vesalio, LLC.
Polaris Market Research has segmented the neurothrombectomy devices market report on the basis of product, end use, and region:
By Product Outlook (Revenue - USD Million, 2020-2034)
Clot Retrievers
Aspiration/Suction Devices
Vascular Snares
By End Use Outlook (Revenue - USD Million, 2020-2034)
Hospitals
Emergency Clinics
Ambulatory Surgical Centers
By Regional Outlook (Revenue - USD Million, 2020-2034)
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Neurothrombectomy Devices Market Insights